{"id":3843,"date":"2020-06-23T10:05:35","date_gmt":"2020-06-23T01:05:35","guid":{"rendered":"https:\/\/www.peptide.co.jp\/en\/?p=3843"},"modified":"2023-08-29T10:15:47","modified_gmt":"2023-08-29T01:15:47","slug":"4123","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/4123.html","title":{"rendered":"SARS-CoV \/ SARS-CoV-2 Main Protease Fluorogenic Substrate"},"content":{"rendered":"

Peptides Institute Inc. is pleased to announce three types of substrates for the SARS-CoV main protease (SARS-CoV Mpro<\/sup> or 3CLpro<\/sup>) and SARS-CoV-2 main protease (SARS-CoV-2 Mpro<\/sup>). Protease activity can be measured by observing the increase in fluorescence by the main protease cleaving the substrate, useful in the research of inhibitors.
\n\u3000
\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus of a new coronavirus infection (COVID-19), which has been spreading worldwide since the end of 2019. When a virus infects a host cell, the RNA from the virus translates a large precursor protein. The precursor protein is cleaved by various proteases, and becomes a functional protein required for virus growth such as RNA-dependent RNA polymerase. SARS-CoV-2 Mpro, which is also one of the cleavage products, plays a major role in cleavage of precursor proteins and is an essential protease for viral growth. Therefore, this \u201cmain protease\u201d inhibitor may be an antiviral drug and is being developed all over the world.
\n\u3000
\n\u3000<\/p>\n

Dabcyl-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu(Edans)-NH2<\/sub><\/a><\/h3>\n

Fluorogenic substrate using FRET of SARS-CoV \/ SARS-CoV-2 Mpro<\/sup><\/i>1),2),3)<\/sup>
\n\u3000
\nThe precursor protein sequence, Thr-Ser-Ala-Val-Leu-Gln \u2193 Ser-Gly-Phe-Arg-Lys-Met [\u2193 is a cleavage site] and a fluorescent group (Edans) and a quenching group (Dabcyl) are introduced. SARS-CoV Mpro<\/sup> cleaves the Gln-Ser sequence between the fluorescent and quencher groups, resulting in increased fluorescence. By observing this fluorescence, the protease activity can be measured [KM<\/sub>=17\u03bcM, kcat=1.9s-1<\/sup> (kinetic parameter for SARS-CoV Mpro<\/sup>)]1)<\/sup> [KM<\/sub>=28\u03bcM (SARS-CoV-2 Kinetic parameters for Mpro<\/sup>)].3)<\/sup>
\n\u3000
\n\"SARS<\/p>\n

Figure 1. Method of measuring protease activity of SARS-CoV\/SARS-CoV-2 Mpro<\/sup> quenching fluorogenic substrate using FRET.<\/p>\n\n\n\n\n
Code<\/td>\nProduct Name<\/td>\nQuant<\/td>\n<\/tr>\n
3249-v<\/a><\/td>\nDabcyl-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu(Edans)-NH2<\/sub><\/td>\n1 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u3000
\n\u3000<\/p>\n

Ac-Abu-Tle-Leu-Gln-MCA<\/a>\u30fbAc-Thz-Tle-Leu-Gln-MCA<\/a><\/h3>\n

\nFluorogenic substrate for SARS-CoV \/ SARS-CoV-2 Mpro<\/sup><\/i> 4)<\/sup>
\n\u3000
\n4-methylcoumarin-7-amide (MCA) type fluorogenic substrate in which aminomethylcoumarin (AMC) is introduced into two sequences with high affinity for SARS-CoV-2 Mpro<\/sup>, as reported by Drag et al. When the non-fluorescent MCA-bound substrate is cleaved by SARS-CoV-2 Mpro<\/sup>, AMC with strong fluorescence is released. By observing this fluorescence, protease activity can be measured. (Ex: 380nm \/ Em: 460nm)
\n\u3000<\/p>\n\n\n\n\n\n
Code<\/td>\nProduct Name<\/td>\nQuant<\/td>\n<\/tr>\n
3250-v<\/a><\/td>\nAc-Abu-Tle-Leu-Gln-MCA<\/td>\n1 mg<\/td>\n<\/tr>\n
3251-v<\/a><\/td>\nAc-Thz-Tle-Leu-Gln-MCA<\/td>\n1 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u3000
\n\u3000<\/p>\n

Other CoV related products<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n
Code<\/td>\nProduct Name<\/td>\nQuant<\/td>\n<\/tr>\n
3252-v<\/a><\/td>\nZ-Arg-Leu-Arg-Gly-Gly-MCA (Substrate for PLPro<\/sup>)<\/td>\n1 mg<\/td>\n<\/tr>\n
3206-v<\/a><\/td>\nUbiquitin-MCA (Substrate for PLPro<\/sup>)<\/td>\n50 \u03bcg<\/td>\n<\/tr>\n
3155-v<\/a><\/td>\nBoc-Arg-Val-Arg-Arg-MCA (Substrate for Furin)<\/td>\n5 mg<\/td>\n<\/tr>\n
3159-v<\/a><\/td>\nPyr-Arg-Thr-Lys-Arg-MCA (Substrate for Furin)<\/td>\n5 mg<\/td>\n<\/tr>\n
3099-v<\/a><\/td>\nAMC (Reference Compound)<\/td>\n5 mg<\/td>\n<\/tr>\n
3253-v<\/a><\/td>\nAc-Abu-D<\/span>-Tyr-Leu-Gln-VS (Inhibitor for Mpro<\/sup>)<\/td>\n1 mg<\/td>\n<\/tr>\n
4041<\/a><\/td>\nLeupeptin (Inhibitor for Serine Protease)<\/td>\n25 mg<\/td>\n<\/tr>\n
4321-v<\/a><\/td>\nE-64-d (Inhibitor for Thiol Protease)<\/td>\n5 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u3000<\/p>\n

<\/div>\n
<\/div>\n

For questions and inquiries regarding this article<\/a><\/Div>
\n
Author: Yukie Nohara<\/Div>
\n\u3000<\/p>\n
\n
    \n
  1. C.-J. Kuo, Y.-H. Chi, J.T.-A. Hsu, and P.-H. Liang, Biochem. Biophys. Res. Commun.<\/i>, 318<\/b>, 862 (2004).<\/li>\n
  2. L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, and R. Hilgenfeld, Science<\/i>, 368<\/b>, 409 (2020).<\/li>\n
  3. M. D. Sacco, C. Ma, P. Lagarias, A. Gao, J. A. Townsend, X. Meng, P. Dube, X. Zhang, Y. Hu, N. Kitamura, B. Hurst, B. Tarbet, M. T. Marty, A. Kolocouris, Y. Xiang, Y. Chen, and J. Wang, Sci Adv.,<\/i> 6<\/b>, eabe0751 (2020).<\/li>\n
  4. W. Rut, K. Groborz, L. Zhang, X. Sun, M. Zmudzinski, B. Pawlik, X. Wang, D. Jochmans, J. Neyts, W. M\u0142ynarski, R. Hilgenfeld, and M. Drag, Nat. Chem. Biol.<\/i>, 17<\/b>, 222 (2021).<\/li>\n","protected":false},"excerpt":{"rendered":"

    Peptides Institute Inc. is pleased to announce three types of substrates for the SARS-CoV main protease (SARS- […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3843"}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3843"}],"version-history":[{"count":31,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3843\/revisions"}],"predecessor-version":[{"id":4927,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3843\/revisions\/4927"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=3843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=3843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}